Vice President, Clinical Development
Company: Trillium Therapeutics
Posted on: January 8, 2021
SummaryTrillium Therapeutics is a clinical stage immuno-oncology
company based in Cambridge, MA and Toronto, ON. Following recent
promising clinical data updates and after raising over $300 million
in 2020, the Company is now embarking on a substantial
organizational scale-up to initiate a phase 2 program across a
range of cancer indications. The Company is seeking a new Vice
President, Clinical Development, who will oversee one or more key
clinical development programs. The position will report into the
CMO and will be based in Cambridge, MA.The CompanyTrillium
Therapeutics (NASDAQ: TRIL) is a clinical stage biotechnology
company developing next generation immunotherapies targeting CD47,
a checkpoint of the innate immune system. Immunotherapy is a
rapidly evolving field that is redefining cancer care by harnessing
a patient's own immune system to eliminate tumor cells. First
generation immunotherapies, targeting the adaptive immune system
via T cell checkpoint inhibitors, have been enormously successful
scientifically (2018 Nobel Prize), clinically (achieving real cure
rates), and commercially (soon to be the largest drug class ever).
CD47 is now emerging as one of the most promising next generation
immuno-oncology targets.Trillium has two highly differentiated CD47
blockers in development that - unlike other CD47 agents - have
shown unique monotherapy activity across a range of hematologic
malignancies. Under new leadership, Trillium has undergone a
wide-ranging transformation program, including a major strategy
reset. In 2020, the company raised over $300M, secured a strategic
investment from Pfizer, and has been among the top performers on
NASDAQ. Nearing completion of ongoing dose escalation studies,
Trillium is now scaling up its organization to initiate a phase 2
program across several cancer indications.Accountabilities
- Provide leadership and coordination with key research functions
to one or more drug development programs.
- In collaboration with the Clinical Operations lead, lead and
coordinate study activities in the program.
- Lead development of the Clinical Strategy/Clinical Development
Plan and provide medical oversight of protocol development, study
conduct and data generation, as well as reporting.
- Oversee Phase I-III clinical development programs to ensure
that regulatory requirements and quality standards are met. Strive
to maintain or exceed compliance obligations for Good Clinical
Practices guidelines and standard company operating
- Act as a company representative interacting with external
scientific leaders and regulatory authorities for assigned
- Search and analyze medical literature. Write/review abstracts,
manuscripts, etc., for publications and/or presentation at
- Lead/participate in investigator meetings and advisory
committee meetings as needed.
- Lead/participate in strategic review and input into documents
(such as protocols, CRFs, Statistical Analysis Plans, CSRs) to
ensure scientific/medical accuracy and consistency with clinical
- Integrate preclinical information (pharmacology, toxicology,
pharmacokinetics) and interpret implications for clinical
development as articulated in the Investigator's Brochure and
- Co-lead product safety review committees as appropriate.
- Provide consultation on medical subjects to investigators and
other company personnel, and apply medical knowledge to guide the
safe, ethical, and efficient conduct of trials.
- Participate in due diligence efforts for clinical partnerships
and/or in-licensing opportunities.
- Work with specific clinical and research partners to facilitate
seamless execution of collaborative efforts.
- May supervise other Medical Directors and/or Clinical
- MD or equivalent.
- Subspecialty training in a discipline relevant for
oncology/hematology therapeutic area.
- Demonstrated potential or ability to design, initiate, and
conduct clinical studies.
- 4-7 years of proven experience as a study director in the
industry, with experience in phase I/II oncology clinical trials
required, phase III experience preferred.
- Proven ability to analyze and interpret efficacy and safety
data relating to oncology.Desired:
- Board-certification in medical oncology/hematology.
- MD-PhD and strong basic/translational science acumen in a
relevant field, demonstrated by the respective publication
- Experience in regulatory interactions throughout the different
phases of development.
- Experience and solid understanding of drug development strategy
and process.Personal Attributes
- Able to work across many interfaces (clinical/clinical
operations, clinical/project management, clinical/regulatory,
- Demonstrated strong interpersonal skills, ability to influence,
and the ability to function in a global team environment.
- Strong and effective communication skills (written and verbal),
with excellent medical/scientific writing skills
- Strong integrity and a commitment to improving patient
- Must be willing and able to be "hands-on", and can thrive in a
matrixed, fast-paced business environment.
- Ability to work effectively with other company leaders and
develop strong working relationships with them.
- Once routine travel resumes, willingness and ability to travel
up to 30% of time.How to ApplyPlease send your resume and cover
letter to email@example.com with the title of the
role in the subject line. Kindly note that phone calls and third
parties are not accepted.
Keywords: Trillium Therapeutics, Cambridge , Vice President, Clinical Development, Healthcare , Cambridge, Massachusetts
Didn't find what you're looking for? Search again!